Anavex fell 36% after Europe CHMP issued a negative trend vote and delayed its Alzheimer drug decision to December. Retail traders were split, citing leadership concerns and cash pressure, but some argued the delay is a positive sign since the application remains active and may go to re-examination. The company says it will seek review once formal opinion is issued.